ArticleBMC cardiovascular disorders2025
Plasma microRNA-210 is associated with VEGF-A and EphrinA3 and relates to coronary collateral circulation in patients with coronary heart disease: a cross-sectional study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive Biomarkers for Coronary Collateral Circulation Development After Myocardial Infarction.International journal of molecular sciences · 2026Review
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explored the interrelationships among vascular endothelial growth factor A (VEGF-A), microRNA-210 (miR-210), and EphrinA3 in the plasma of patients with coronary heart disease (CHD), and their collective influence on coronary collateral circulation (CCC) development.
methodsWe enrolled 253 patients with ≥ 90% stenosis in at least one coronary artery, stratified into good CCC (n = 99) and poor CCC (n = 154) groups according to the Rentrop grading system. Plasma concentrations of miR-210, VEGF-A, and EphrinA3 were quantified via qRT-PCR and ELISA. The associations between these biomarkers and CCC status were evaluated through correlation analysis, multivariate regression, and mediation analysis.
resultsGood CCC patients demonstrated significantly elevated plasma miR-210 (1.936 [1.099-4.118] vs. 1.272 [0.792-2.081], p < 0.001) and VEGF-A levels (3119.655 ± 850.995 vs. 2910.440 ± 713.218 pg/mL, p = 0.038), alongside reduced EphrinA3 levels (529.594 ± 143.037 vs. 584.657 ± 127.182 pg/mL, p = 0.002) compared to poor CCC patients. ROC analysis revealed AUCs of 0.656 (95% CI: 0.589-0.724) for miR-210, 0.563 (95% CI: 0.489-0.638) for VEGF-A, and 0.632 (95% CI: 0.560-0.705) for EphrinA3, which improved to 0.747, 0.696, and 0.744 respectively after adjustment for confounders. In fully adjusted multivariate models, miR-210 maintained a robust positive association with good CCC (OR: 1.558, 95% CI: 1.257-1.931, p < 0.001), with its highest tertile conferring 4.58-fold increased odds compared to the lowest tertile. Conversely, EphrinA3 exhibited a significant negative association (OR: 0.993, 95% CI: 0.990-0.997, p < 0.001), with its highest tertile linked to 79.4% reduced odds of good CCC. VEGF-A showed a modest association (OR: 1.001, p = 0.043). Notably, mediation analysis revealed that miR-210 functions as a pivotal intermediary in pathways connecting both VEGF-A and EphrinA3 to CCC formation, mediating 77.18% and 49.90% of their respective effects.
conclusionsPlasma miR-210 levels exhibit a strong association with coronary collateral circulation development and represent a promising biomarker for CCC formation in patients with severe coronary stenosis. The influence of VEGF-A and EphrinA3 on CCC formation appears to be predominantly mediated through miR-210, highlighting its central role in coronary collateralization pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.